|Find A PhysicianHome | Library | myDownstate | Newsroom | A-Z Guide | E-mail | Contact Us | Directions|
Research Activities and Grants
Principal Investigator, Miller, ST, New York State Department of Health, Expanded Comprehensive Sickle Cell Services, Contract #C008267, Renewed July 1, 1999 - June 30, 2002
Principal Investigator (Local) Miller, ST, Dept. of Health and Human Services, Maternal and Child Health Bureau, MCHB 99-007 (Subcontract, New York State Dept. of Health), Improvement and Integration of Health Services within a State for Infants and Young Children with Sickle Cell Disease, September 1,1999-May 31, 2002
Principal Investigator, Miller ST National Institutes of Health, Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)-Clinical Center, Contract No. NO1-HB-07156, September 1,2000-December 31, 2009
Principal Investigator (Local) Miller ST, Medical College of Georgia (subcontract), National Institutes of Health, Optimizing Stroke Prevention In Children with Sickle Cell Disease (STOP2), Robert Adams, M.D., Principal Investigator, NIH Contract #2 UO1-HL52193-06A1, MCG Subcontract MCG-STOP2-000967-16, July 1, 2000-June 30, 2004
Principal Investigator (Local) Miller ST, Washington University, St. Louis (subcontract), WU-04-56 PO#29884B, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Contract U01-NS042804-01A1, Silent Infarct Transfusion Trial (SITT), Michael Debaun, MD, Principal Investigator, September 30, 2003-June 30, 2010
Local Principal Investigator, Miller ST, Quintiles, Inc. Icagen, Inc. ICA-17043-10, A Phase III, Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell Disease, 4/14/05-4/07
Medical Consultant, Miller ST, New England Research Inc., NIH/NHLBI 1 U1O HL083721-01, Sickle Cell Disease Clinical Research Network-Data Coordinating Center, Donald Brambilla, Principal Investigator; April 10, 2006-March 31, 2011
Local Principal Investigator, St. Jude Children's Research Hospital, NIH/NHLBI, Principal Investigator Russell Ware MD PhD, 1U01 HL078787-01A1, Stroke with Tranfusions Changing to Hydroxyurea (SWITCH) October 2005-July 31, 2007; Renewal Pending
Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Predicting adverse outcomes in children with sickle cell disease: a report from the Cooperative Study (CSSCD). N Engl J Med 2000;342:83-9.
Sakhalkar VS, Rao SP, Gottessman SRS, Miller ST. Hemophagocytosis and granulomas in a child with Down syndrome. J Pediatr Hematol/Oncol 2001;23:623-5.
Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle cell anemia. J Pediatr 2001;139:785-9.
Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt D, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younkin DP, Zimmerman RA, DeBaun MR. "Silent infarction" as a risk factor for overt stroke in children with sickle cell disease: a report from the Cooperative Study (CSSCD). J Pediatr 2001;139:385-90.
Files B, Brambilla D, Kutlar A, Miller S, Vichinsky E, Wang W, Granger S, Adams RJ. Longitudinal changes in ferritin during chronic transfusion: A report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol/Oncol 2002;24:284-90.
Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR. Longitudinal changes in brain MRI findings in children with sickle cell disease. Blood 2002;99:3014-3018.
Miller ST, Wright E, Brambilla D, Adams RJ. Stroke prevention trial in sickle cell anemia: Comments on effects of chronic transfusion on pain-Reply (letter). J Pediatr 2002;141:743.
Saxena VR, Mina R, Moallem HJ, Rao SP, Miller ST. Systemic lupus erythematosus in children with sickle cell disease. Amer J Pediatr Hematol/Oncol 2003;25:668-71.
Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ. Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol/Oncol 2003;25:622-8.
Miller ST, Rao SP. Acute chest syndrome, transfusion, and neurological events in children with sickle cell disease (letter). Blood 2003;102:1556.
Reid ME, Storry JR, Sausais L, Tossas E, Rios M, Hue-Roye K, Gloster ES, Miller ST, Wolf C, Lomas-Francis C. DAK, a new low-incidence antigen in the Rh blood group system. Transfusion. 2003;43(10):1394-7.
Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliot J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong W, Wang WC. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis and antibiotic resistance. J Pediatr 2003;143:438-44.
Goyal M, Miller ST, Hammerschlag MR, Gelling M, Gaydos CA, Wood BJ, Reznik T, Rao SP. Stroke in children with sickle cell disease: Lack of association with Chlamydia pneumoniae infection. Pediatrics 2004;113:e318-e321.
Sakhalkar VS, Rao SP, Weedon J, Miller ST. Elevated plasma sVCAM-1 levels in children with sickle cell disease: impact of chronic transfusion therapy. Am J Hematol. 2004 May;76(1):57-60.
The Optimizing Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusion to prevent stroke in sickle cell disease. N Engl J Med 2005;353:25-34. (Acknowledged as Investigator, Miller ST, and member of Manuscript Preparation Committee)
Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, Adams RJ. Stroke Prevention trial in sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006;108:847-52.
Seeyave D, Desai N, Miller S, Rao SP, Piecuch S. Delayed hemolytic transfusion reaction with hyperhemolysis syndrome and sepsis in a patient with sickle cell anemia. J National Med Assoc 2006 Oct;98:1697-9.
Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Brit J Hematol 2006;134:333-9.
Brambilla DG, Miller ST, Adams RJ for the STOP and STOP 2 Investigative Teams. Intra-individual variation in blood flow velocities detected by transcranial Doppler ultrasonography in children with sickle cell disease. Pediatr Blood Cancer 2007 Jan 22 (Epub ahead of print).
Quinn C, Miller ST. Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematol Oncol Clin N Amer 2004;18(6):1339-54.
Miller ST. Sickle Cell Disease. In Saunders Manual of Pediatric Practice. Finberg L, ed., W.B. Saunders Co., Philadelphia Pa., 1998, pp 407-13. Edition 2, 2002, pp 472-9.
Miller ST. Thalassemias. In Saunders Manual of Pediatric Practice. Finberg L, ed., W.B. Saunders Co., Philadelphia Pa., 1998, pp 413-17. Edition 2, 2002, pp 479-84.
Miller ST. Sickle cell anemia with fever. In Atlas of Pediatric Emergency Medicine. Shah BR and Lucchesi M, eds. The McGraw-Hill Companies, New York, NY, 2006, pp 463-5.
Miller ST. Sickle cell anemia with acute pain episode. In Atlas of Pediatric Emergency Medicine. Shah BR and Lucchesi M, eds. The McGraw-Hill Companies, New York, NY, 2006, pp 466-8.
Miller ST. Sickle cell anemia with acute chest syndrome. In Atlas of Pediatric Emergency Medicine. Shah BR and Lucchesi M, eds. The McGraw-Hill Companies, New York, NY, 2006, pp 469-70.
Miller ST. Sickle cell anemia with priapism. In Atlas of Pediatric Emergency Medicine. Shah BR and Lucchesi M, eds. The McGraw-Hill Companies, New York, NY, 2006, pp 471-3.
Miller ST. Sickle cell anemia with cerebrovascular disease. In Atlas of Pediatric Emergency Medicine. Shah BR and Lucchesi M, eds. The McGraw-Hill Companies, New York, NY, 2006, pp 474-6.
Guidelines for the Treatment of People with Sickle Cell Disease. The Sickle Cell Advisory Committee of the Genetic Network of New York, Puerto Rico and the Virgin Islands, New York State Department of Health, March 2002. Download the guide (PDF).